Zura Bio Limited (ZURA) Financial Ratios
5 years of historical data (2021–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
4.21
↑+58% vs avg
5yr avg: 2.66
30Y Low1.2·High4.9
ROE
↓
-76.0%
-2% vs avg
5yr avg: -74.2%
30Y Low-210%·High6%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ZURA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Zura Bio Limited currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $295M | $493M | $188M | $154M | — | — |
| Enterprise Value | $186M | $384M | $11M | $55M | — | — |
| P/E Ratio → | -4.28 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | 4.21 | 4.86 | 1.17 | 1.94 | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ZURA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
ZURA Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -76.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -76.0% | -76.0% | -43.7% | -210.0% | -47.6% | 6.5% |
| ROA | -67.7% | -67.7% | -37.4% | -113.8% | -35.3% | 6.0% |
| ROIC | — | — | — | — | -35.9% | — |
| ROCE | -57.5% | -57.5% | -45.9% | -176.5% | -41.6% | -0.8% |
ZURA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $109M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.08 | -1.10 | -1.25 | — | -0.01 |
| Net Debt / EBITDA | — | — | — | — | — | -0.09 |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — |
Net cash position: cash ($109M) exceeds total debt ($0)
ZURA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Zura Bio Limited's current ratio of 9.05x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 4.97x to 9.05x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 9.05 | 9.05 | 9.16 | 4.97 | 0.12 | 4.23 |
| Quick Ratio | 9.05 | 9.05 | 9.16 | 4.97 | 0.12 | 4.23 |
| Cash Ratio | 8.82 | 8.82 | 9.04 | 4.92 | 0.11 | 2.68 |
| Asset Turnover | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
ZURA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Zura Bio Limited does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $94M | $75M | $33M | $17M | $17M |
Peer Comparison
Compare ZURA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ZURAYou | $295M | -4.3 | — | — | — | — | -76.0% | — | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 ARQT | $3B | -158.9 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 DAWN | $2B | -20.7 | — | — | 89.1% | -80.8% | -22.7% | -30.5% | — |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 NUVL | $8B | -17.5 | — | — | — | — | -36.7% | -32.5% | — |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 LLY | $921B | 42.5 | 30.6 | 102.7 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 REGN | $74B | 17.1 | 17.8 | 18.1 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 5 years · Updated daily
See ZURA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ZURA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ZURA vs IMVT
Side-by-side business, growth, and profitability comparison vs Immunovant, Inc..
Start ComparisonZURA — Frequently Asked Questions
Quick answers to the most common questions about buying ZURA stock.
What is Zura Bio Limited's P/E ratio?
Zura Bio Limited's current P/E ratio is -4.3x. This places it at the 50th percentile of its historical range.
What is Zura Bio Limited's ROE?
Zura Bio Limited's return on equity (ROE) is -76.0%. The historical average is -74.2%.
Is ZURA stock overvalued?
Based on historical data, Zura Bio Limited is trading at a P/E of -4.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.